10-Q: Finch Therapeutics Reports Q2 2024 Results, Focuses on IP Monetization After Strategic Shift

Finch Therapeutics continues to pursue intellectual property monetization after ceasing clinical development, reporting a net loss of $4.834 million for the quarter ended June 30, 2024, but also securing a favorable jury verdict in a patent infringement case.

Summary

• Finch Therapeutics Group, Inc. reported its financial results for the second quarter of 2024.
• Following a strategic reprioritization in January 2023, the company is now focused on realizing the value of its intellectual property estate and other assets.
• The company has wound down its clinical development efforts and significantly reduced expenses.
• For the three months ended June 30, 2024, Finch reported a net loss of $4.834 million, compared to a net loss of $6.950 million for the same period in 2023.
• General and administrative expenses decreased to $6.109 million from $8.877 million year-over-year.
• Total other income, net was $1.275 million, compared to $2.931 million in the prior year.
• The company's cash and cash equivalents totaled $16.035 million as of June 30, 2024.
• Finch believes its existing cash will fund operating expenses and capital expenditure requirements into 2025.
• A jury verdict on August 9, 2024, awarded Finch and UMN $25.0 million upfront and $0.815 million in running royalties in a patent infringement case against Rebiotix.
• The company expects Rebiotix to file post-trial motions and pursue an appeal.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is still operating at a loss, it has reduced its losses compared to the previous year and secured a favorable jury verdict. However, its future is highly dependent on the outcome of litigation and intellectual property monetization, which are inherently uncertain.

Positives

• Net loss decreased from $6.950 million in Q2 2023 to $4.834 million in Q2 2024.
• General and administrative expenses decreased by $2.768 million year-over-year.
• The company secured a favorable jury verdict in a patent infringement case, awarding $25.0 million upfront and $0.815 million in royalties.
• Finch believes its existing cash will fund operating expenses and capital expenditure requirements into 2025.

Negatives

• The company reported a net loss of $4.834 million for Q2 2024.
• Total other income, net decreased by $1.6 million year-over-year.
• The company's future is heavily reliant on the outcome of litigation and intellectual property monetization.

Risks

• The company's future is heavily reliant on the outcome of litigation and intellectual property monetization, which are inherently uncertain.
• Rebiotix is expected to file post-trial motions and pursue an appeal, which could delay or reduce the financial benefits of the jury verdict.
• The company may need additional funding to support its operating activities.
• The company's common stock was suspended from trading on the Nasdaq, which may adversely affect the stock price and liquidity.

Future Outlook

Finch Therapeutics expects to continue to incur significant losses for the foreseeable future as it attempts to realize the value of its intellectual property estate and other assets. The company believes its existing cash will fund operating expenses and capital expenditure requirements into 2025, but this is largely dependent on the outcome of the ongoing litigation against Rebiotix.

Management Comments

• The company is focused on realizing the value of its intellectual property estate through licensing its technology to collaboration partners and enforcing its patent rights against infringing parties.
• The company does not currently expect to progress any product candidate through clinical trials or commercial approval and does not currently expect to generate any revenue from product sales.

Industry Context

Finch's strategic shift reflects the challenges and high costs associated with bringing microbiome-based therapies to market. The company is now focusing on leveraging its intellectual property, a strategy that may be more capital-efficient in the current environment. The outcome of the patent litigation against Rebiotix could set a precedent for the value of microbiome-related intellectual property.

Comparison to Industry Standards

• It is difficult to compare Finch's current financial performance to industry standards due to its strategic shift away from clinical development.
• Many biotech companies in the microbiome space are focused on clinical trials and commercialization, while Finch is primarily focused on IP monetization.
• Comparable companies in the IP monetization space include patent assertion entities, but their business models and financial metrics are not directly comparable to Finch's situation.
• The $25.0 million upfront payment and $0.815 million in running royalties awarded in the Rebiotix case could be compared to licensing deals in the pharmaceutical industry, but the specific terms and conditions vary widely.

Legal Proceedings

• On December 1, 2021, Rebiotix Inc. and Ferring Pharmaceuticals Inc. filed a complaint against the company in the U.S. District Court for the District of Delaware.
• On August 9, 2024, the jury rendered a verdict finding that Rebiotix had infringed the asserted claims, that such infringement was willful, that one claim each from the 309 Patent and the 080 Patent was invalid, and that the remaining claims were not invalid.
• The jury awarded royalty damages to the company and UMN in the amount of a $25.0 million upfront payment and $0.815 million in running royalties for commercial sales of Rebyota for the period between its commercial launch through the date of trial.
• The company and UMN expect to seek enhanced damages, attorneys fees, costs, and prejudgment interest, as well as post-judgment relief for Ferring's ongoing infringement.
• The company expects Rebiotix to file post-trial motions, including seeking resolution of their pending motion to amend the pleadings and their equitable estoppel defense as to the UMN patent.
• The company also expects Rebiotix to pursue an appeal of any judgment entered on the jury's verdict.

Stakeholder Impact

• Shareholders: The jury verdict is a positive development, but the company's future remains uncertain.
• Employees: The company has significantly reduced headcount as part of its strategic reprioritization.
• Customers: The company is no longer focused on developing and commercializing products.
• Suppliers: The company has terminated vendor contracts as part of its strategic reprioritization.
• Creditors: The company believes its existing cash will fund operating expenses and capital expenditure requirements into 2025.

Next Steps

• The company expects Rebiotix to file post-trial motions and pursue an appeal of the jury verdict.
• The company and UMN expect to seek enhanced damages, attorneys fees, costs, and prejudgment interest, as well as post-judgment relief for Ferring's ongoing infringement.
• The company will continue to explore opportunities to realize the value of its intellectual property and microbiome assets through strategic partnerships and academic collaborations.

Key Dates

Keywords

intellectual property, litigation, monetization, financial results, patent infringement, microbiome, Finch Therapeutics